查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030007

腫瘤和免疫學流式細胞技術市場－全球產業規模、佔有率、趨勢、競爭格局、機會、預測：按類型、技術、產品、應用、最終用戶、地區和競爭格局分類，2021-2031年

Flow Cytometry in Oncology and Immunology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, Segmented By Type, By Technology, By Offering, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球腫瘤學和免疫學流式細胞技術市場預計將從 2025 年的 36.3 億美元成長到 2031 年的 58.4 億美元，複合年成長率為 8.25%。

這項技術利用螢光和光散射特性來識別細胞的功能、狀態和類型，是快速、全面評估細胞群體的重要實驗室技術。它在疾病診斷、預後評估和治療監測等專業醫學領域中發揮著至關重要的作用。市場擴張的主要驅動力是全球癌症和免疫疾病發生率的上升，這推動了對先進研究和診斷設備的需求。此外，生物標記鑑定和個人化醫療研發投入的增加，以及儀器功能的持續技術進步，也大大促進了市場需求。國際細胞計量學會（ISAC）報告稱，其年會CYTO 2025吸引了來自40多個國家的1600多名與會者，這表明該領域備受關注。

市場概覽
預測期 2027-2031
市場規模：2025年 36.3億美元
市場規模：2031年 58.4億美元
複合年成長率：2026-2031年 8.25%
成長最快的細分市場 軟體
最大的市場 北美洲

阻礙該市場成長的主要障礙在於購買最先進的流式細胞技術設備及相關試劑需要大量的資金投入。如此高的初始成本可能會限制這項技術的應用，尤其是在發展中地區的小規模實驗室和醫療機構。此外，管理這些複雜系統並準確解讀所得數據需要訓練有素的專業人員，這也為該技術的廣泛應用帶來了持續的營運挑戰。

市場促進因素

全球流式細胞技術市場正受到其在癌症診斷和研究中日益廣泛的應用的顯著推動。隨著新治療方法的出現，這項技術已成為深入了解癌細胞特徵、追蹤疾病進展和評估治療效果的關鍵手段。隨著腫瘤學的日益複雜，個人化醫療和生物標記識別需要精密的儀器，而流式細胞技術已成為臨床和研究領域的核心要素。例如，美國癌症研究協會 (AACR) 發布的《2025 年癌症進展報告》指出，在 2024 年 7 月 1 日至 2025 年 6 月 30 日期間，美國食品藥品監督管理局 (FDA)核准了20 種新的抗癌藥物、8 種現有癌症治療方法的新適應症以及 2 種新的早期檢測設備。核准診斷和治療方法的激增直接推高了對流式細胞技術的需求，以支持這些方法的開發和應用。

同時，流式細胞技術系統的持續技術進步正成為推動細胞分析拓展的重要引擎。這些創新圖了靈敏度更高、檢測參數更多、操作流程更簡化的儀器，滿足了醫療專業人員和科學家不斷變化的需求。這些改進使得對細胞群進行精確而詳細的分析成為可能，這對於揭示各種癌症類型和複雜的免疫反應至關重要。例如，2025年3月，貝克曼庫爾特生命科學公司發布了CytoFLEX mosaic光譜檢測模組，這是一款開創性的模組化頻譜流式細胞技術系統，最多可配備88個檢測通道。這些突破性技術透過提供卓越的數據洞察和簡化的工作流程，正在推動其更廣泛的應用。此外，強而有力的資金支持也反映了對這些領域研究的堅定承諾。 2026年3月，馬剋癌症研究基金會將其面向全球研究人員的「新興領袖獎」的津貼總額提高至每位獲獎者100萬美元，分四年發放。

市場挑戰

購買先進的流式細胞技術設備和必要的試劑需要大量資金，這成為全球腫瘤學和免疫學領域流式細胞技術市場擴張的主要障礙。這些設備的初始成本通常非常高昂，不僅包括主要設備，還包括必要的配件、安裝費和持續的維護合約。因此，沉重的經濟負擔成為許多潛在用戶進入該領域的重大障礙。

高昂的初始成本直接限制了市場成長，小規模的研究實驗室、教育機構和醫療機構，尤其是在開發中國家，造成了不成比例的影響。這些機構的預算通常較為緊張，即使新技術能為研發和診斷帶來顯著益處，也難以採用。這一財務障礙限制了流式細胞技術平台的廣泛應用和定期更新，阻礙了其整體市場滲透。道明證券 (TD Securities) 2025 年對醫院高層進行的一項調查顯示，40% 的受訪者計劃減少或推遲資本支出。這項結果表明，經濟壁壘直接阻礙了流式細胞技術等尖端設備融入醫療機構的日常臨床和研究運作。

市場趨勢

腫瘤學和免疫學領域全球流式細胞技術市場的關鍵趨勢之一是對自動化、高通量系統的日益依賴，這主要源於對細胞分析更高擴充性和生產力的需求。這些系統透過簡化複雜流程並減少人工操作，能夠處理更大樣本量的樣本。這種自動化趨勢涵蓋了從樣本製備到資料收集的每一個步驟，使醫療專業人員和科學家能夠加速診斷和研究工作流程。例如，IntuitionLabs.ai 於 2026 年 4 月發布的《Dotmatics 平台與人工智慧在實驗室資訊學中的整合》報告中提到，一位客戶使用 Dotmatics Luma 平台在一年內處理了 420 億筆流式細胞技術儀資料記錄。這前所未有的數據量清楚地展現了這些系統強大的數據處理能力，而這對於臨床和實驗室環境中的大規模篩檢、藥物研發和精細免疫分析至關重要。

同時，先進數據分析和人工智慧的引入正在徹底改變從流式細胞技術生成的複雜資料集中提取有效資訊的方式。這些現代儀器產生高維度數據，使得傳統的人工評估方法越來越難以管理。機器學習和人工智慧為生物標記發現、自動細胞群識別和異常檢測提供了先進的工具，從而提高了數據解讀的速度和深度。這項技術飛躍使得治療反應和疾病狀態的表徵更加精準，推動該領域從簡單的表現型分析邁向預測分析。為了佐證這項轉變，Menlo Ventures 於 2025 年 10 月進行的一項調查顯示，22% 的醫療機構表示會採用特定領域的人工智慧工具。這表明醫療保健產業對先進分析能力的接受度正在不斷提高，並將直接影響人工智慧在腫瘤學和免疫學領域解讀流式細胞技術數據的應用方式。

目錄

第1章 產品概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球流式細胞技術在腫瘤學和免疫學領域的市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（免疫學、腫瘤學）
    • 依技術（基於細胞的流式細胞技術、基於以微珠為基礎的流式細胞技術）
    • 透過提供（試劑、設備、耗材、軟體）
    • 按應用領域（轉化研究、臨床研究）
    • 按最終用戶分類（醫院、診斷和參考檢查室、製藥和生物技術公司、學術研究機構、受託研究機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美腫瘤和免疫學領域流式細胞技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲腫瘤和免疫學領域流式細胞技術的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區腫瘤和免疫學領域流式細胞技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲腫瘤學和免疫學領域的流式細胞技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲腫瘤與免疫學領域流式細胞技術市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球腫瘤與免疫學流式細胞技術市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Cytek Biosciences, Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • Enzi Biochem Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15020

The Global market for flow cytometry in oncology and immunology is anticipated to expand from USD 3.63 billion in 2025 to USD 5.84 billion by 2031, reflecting a compound annual growth rate of 8.25%. This technology serves as an essential laboratory technique for the swift, multiparametric evaluation of cell populations, utilizing fluorescent and light-scattering properties to define cellular functions, states, and types. It plays a vital role in diagnosing diseases, determining prognoses, and monitoring therapies in these specialized medical domains. Market expansion is largely fueled by the rising worldwide prevalence of cancer and immunological conditions, which drives the need for sophisticated research and diagnostic instruments. Additionally, increasing investments in research and development for biomarker identification and personalized medicine, coupled with ongoing technological upgrades to instrument capabilities, strongly boost market demand. Highlighting the robust interest in this sector, the International Society for Advancement of Cytometry reported that its CYTO 2025 annual congress hosted over 1,600 attendees from more than 40 nations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.63 Billion
Market Size 2031USD 5.84 Billion
CAGR 2026-20318.25%
Fastest Growing SegmentSoftware
Largest MarketNorth America

A major obstacle hindering the growth of this market is the heavy capital investment needed to procure cutting-edge flow cytometry equipment and the related reagents. Such steep upfront costs can limit the uptake of this technology, especially among smaller labs and healthcare facilities in developing areas. Furthermore, the requirement for extensively trained professionals to manage these complex systems and accurately interpret the resulting data poses a continuous operational challenge to widespread adoption.

Market Driver

The Global flow cytometry market is heavily propelled by its broadening uses in cancer diagnostics and research. As novel treatment approaches emerge, this technology has become essential for detailing cancer cell characteristics, tracking disease advancement, and assessing therapeutic efficacy. The growing intricacies of oncology necessitate advanced instruments for personalized medicine and identifying biomarkers, positioning flow cytometry as a core element in clinical and research environments alike. Illustrating this trend, the American Association for Cancer Research (AACR) Cancer Progress Report 2025 noted that between July 1, 2024, and June 30, 2025, the FDA cleared 20 novel anticancer drugs, new applications for eight existing cancer therapies, and two fresh early detection instruments. This surge in cleared diagnostics and treatments directly boosts the need for flow cytometry to assist in their creation and application.

At the same time, continuous technological progress in flow cytometry systems serves as a major growth engine, expanding the limits of cellular examination. These innovations yield devices with upgraded features, including better sensitivity, higher parameter detection, and smoother operational workflows, which meet the shifting demands of medical professionals and scientists. Such improvements allow for the precise and thorough profiling of cell groups, a necessity for decoding varied cancer types and intricate immune reactions. For instance, in March 2025, Beckman Coulter Life Sciences introduced the CytoFLEX mosaic Spectral Detection Module, a pioneering modular spectral flow cytometry system providing up to 88 detection channels. These breakthroughs encourage wider utilization by delivering superior data insights and workflow efficiencies. Additionally, robust financial backing demonstrates a strong dedication to advancing research in these fields; in March 2026, The Mark Foundation for Cancer Research raised the total funding of its globally accessible Emerging Leader Award to $1 million per recipient distributed over a four-year period.

Market Challenge

The substantial financial investment required to purchase sophisticated flow cytometry devices and their necessary reagents acts as a major roadblock to the expansion of the global flow cytometry market in oncology and immunology. The preliminary costs for these setups are often massive, covering not just the primary equipment but also essential accessories, setup fees, and continuous maintenance agreements. Consequently, this heavy economic burden creates a steep barrier to entry for numerous prospective users.

These high initial costs directly limit the growth of the market, disproportionately impacting smaller research labs, educational facilities, and healthcare organizations located in developing nations. Because these entities typically function on tighter budgets, obtaining expensive new technologies proves difficult, even with their clear benefits for research and diagnostics. This financial hurdle restricts the broad implementation and regular updating of flow cytometry platforms, consequently hindering overall market penetration. Highlighting this issue, a 2025 TD Securities poll of hospital leaders revealed that 40% of respondents intended to reduce or postpone their investments in capital equipment. This finding illustrates how economic obstacles directly hinder the assimilation of cutting-edge tools such as flow cytometry into everyday clinical and research operations in medical facilities.

Market Trends

A major trend shaping the global flow cytometry market in immunology and oncology is the rising reliance on automated, high-throughput systems, motivated by a demand for greater scalability and productivity in cell analysis. By simplifying intricate procedures and reducing the need for manual input, these systems make it possible to handle significantly larger quantities of samples. This shift toward automation covers everything from preparing samples to gathering data, empowering medical professionals and scientists to speed up their diagnostic and research workflows. To illustrate, an April 2026 report by IntuitionLabs.ai on the 'Dotmatics Platform & AI Integration in Lab Informatics' highlighted a client who processed 42 billion flow cytometry instrument data records in a single year using the Dotmatics Luma platform. This previously unattainable volume underscores the immense data processing power these systems provide, which is essential for extensive screening, pharmaceutical development, and in-depth immune analysis in clinical and laboratory environments.

Concurrently, the incorporation of advanced data analytics and artificial intelligence is revolutionizing the extraction of meaningful information from the intricate datasets produced by flow cytometry. Because these modern instruments generate highly dimensional data, conventional manual evaluation techniques are becoming increasingly inadequate. Machine learning and AI provide advanced resources for discovering biomarkers, identifying cell populations automatically, and spotting anomalies, thereby boosting both the pace and depth of data interpretation. This technological leap enables a more accurate characterization of treatment reactions and disease conditions, advancing the field from simple phenotyping toward predictive analytics. Supporting this shift, October 2025 research from Menlo Ventures showed that 22% of healthcare institutions had adopted domain-specific AI tools. This points to a growing embrace of sophisticated analytical capabilities across the broader healthcare sector, directly impacting how AI is utilized to interpret flow cytometry data for oncology and immunology.

Key Market Players

  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Cell Signaling Technology, Inc.
  • Cytek Biosciences, Inc.
  • Danaher Corporation
  • DiaSorin S.p.A.
  • Enzi Biochem Inc.
  • Laboratory Corporation of America Holdings
  • Merck KGaA

Report Scope

In this report, the Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Flow Cytometry in Oncology and Immunology Market, By Type

  • Immunology
  • Oncology

Flow Cytometry in Oncology and Immunology Market, By Technology

  • Cell-based flow cytometry
  • Bead-based Flow Cytometry

Flow Cytometry in Oncology and Immunology Market, By Offering

  • Reagents
  • Instruments
  • Consumables Software

Flow Cytometry in Oncology and Immunology Market, By Application

  • Translational Research
  • Clinical Research

Flow Cytometry in Oncology and Immunology Market, By End User

  • Hospitals
  • Diagnostic Laboratories and Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic Research Institutes
  • Contract Research Organizations
  • Others

Flow Cytometry in Oncology and Immunology Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Flow Cytometry in Oncology and Immunology Market.

Available Customizations:

Global Flow Cytometry in Oncology and Immunology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Flow Cytometry in Oncology and Immunology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Immunology, Oncology)
    • 5.2.2. By Technology (Cell-based flow cytometry, Bead-based Flow Cytometry)
    • 5.2.3. By Offering (Reagents, Instruments, Consumables Software)
    • 5.2.4. By Application (Translational Research, Clinical Research)
    • 5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Flow Cytometry in Oncology and Immunology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Technology
    • 6.2.3. By Offering
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Offering
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Offering
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Offering
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Flow Cytometry in Oncology and Immunology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Technology
    • 7.2.3. By Offering
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Offering
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Offering
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Offering
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Offering
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Offering
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia Pacific Flow Cytometry in Oncology and Immunology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Technology
    • 8.2.3. By Offering
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Offering
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Offering
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Offering
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Offering
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Offering
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. Middle East & Africa Flow Cytometry in Oncology and Immunology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Technology
    • 9.2.3. By Offering
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Offering
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Offering
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Offering
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. South America Flow Cytometry in Oncology and Immunology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Technology
    • 10.2.3. By Offering
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Offering
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Offering
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Offering
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Flow Cytometry in Oncology and Immunology Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Becton, Dickinson and Company
  • 15.3. Bio-Rad Laboratories, Inc.
  • 15.4. Cell Signaling Technology, Inc.
  • 15.5. Cytek Biosciences, Inc.
  • 15.6. Danaher Corporation
  • 15.7. DiaSorin S.p.A.
  • 15.8. Enzi Biochem Inc.
  • 15.9. Laboratory Corporation of America Holdings
  • 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer